BIO 2015 Dispatches: Not a bubble, says EY
This article was originally published in Scrip
Despite unprecedented growth in the biotechnology sector in 2014, EY's Global Life Science leader Glen Giovannetti says the market is not likely to implode, but he does expect the amount of money flowing into biotech to normalize over the coming year.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.